|1.||Zauli, Giorgio: 17 articles (06/2014 - 05/2006)|
|2.||Secchiero, Paola: 16 articles (06/2014 - 05/2006)|
|3.||Melloni, Elisabetta: 9 articles (06/2014 - 05/2007)|
|4.||Vassilev, Lyubomir T: 9 articles (01/2011 - 11/2005)|
|5.||di Iasio, Maria Grazia: 7 articles (04/2013 - 05/2006)|
|6.||Tiribelli, Mario: 7 articles (11/2012 - 05/2006)|
|7.||Voltan, Rebecca: 6 articles (06/2014 - 03/2010)|
|8.||Maki, Carl G: 6 articles (01/2014 - 10/2008)|
|9.||Andreeff, Michael: 5 articles (01/2015 - 08/2006)|
|10.||Shen, Hong: 5 articles (01/2014 - 10/2008)|
04/01/2010 - "Our novel and unexpected finding provides important information regarding the efficacy of Nutlin-3 and indicates that patients with tumors deficient in p53 function due to p73 or PTEN loss may benefit from Nutlin-3 treatment."
02/07/2006 - "Nutlin-3 also showed good efficacy against tumors with normal MDM2 expression, suggesting that many of the patients with wild-type p53 tumors may benefit from antagonists of the p53-MDM2 interaction."
10/01/2015 - "The small-molecule inhibitor of p53-Mdm2 interaction, Nutlin-3, is known to be effective against cancers expressing wild-type (wt) p53. "
09/27/2011 - "Nutlin-3a treatment enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation, and combination of reovirus and Nutlin-3a might represent an improved therapy against cancers harbouring wild-type p53."
11/30/2014 - "In this study, we showed that MDM2 inhibitor Nutlin-3 upregulated p53 protein and downregulated FoxM1 expression in several cancer cell lines with wild type TP53 but not in cell lines with mutant TP53. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2014 - "Anti-MDM2 ASO and nutlin-3 were evaluated for their in vitro and in vivo anti-angiogenesis activities in different human breast cancer models with a different p53 status: MCF-7 cell line containing wild-type p53 and MDA-MB-468 cell line containing mutant p53. "
11/20/2012 - "Attractor landscape analysis of the cellular response to DNA damage of the breast cancer cell line MCF7 and the effect of the Mdm2 (murine double minute 2) inhibitor nutlin-3 indicated that nutlin-3 would exhibit limited efficacy in triggering cell death, because the cell death state was not induced to a large extent by simulations with nutlin-3 and instead produced a state consistent with oscillatory p53 dynamics and cell cycle arrest. "
07/01/2011 - "Interestingly, XI-011 acted additively with the MDM2 antagonist Nutlin-3a to inhibit growth of breast cancer cells. "
04/01/2011 - "Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy."
11/01/2014 - "MCF-10A1 and MCF-10CA1a breast cancer cells were treated with Nutlin-3 and TGF-β3, and the effects on tumor cell migration and invasion were studied in transwell and 3D spheroid invasion assays. "
|3.||Retinoblastoma (Glioblastoma, Retinal)
11/01/2007 - "Subconjunctival delivery of nutlin-3 in preclinical models of retinoblastoma confirmed the efficacy of this approach in vivo. "
06/15/2011 - "However, Nutlin-3a cannot be administered systemically to treat retinoblastoma, because it has poor penetration across the blood-ocular barrier. "
06/15/2011 - "Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a."
01/01/2011 - "The Nutlin-3 response of hMDMX transformed retinoblasts was intact and resembled that of retinoblastoma cell lines. "
01/01/2011 - "Although Nutlin-3 is currently in phase I clinical trial for the treatment of retinoblastoma, its effects on normal tissues and cell types remain largely to be determined and will require further investigation in the future years."
|4.||Hematologic Neoplasms (Hematological Malignancy)
04/30/2009 - "Taken together, these data indicate that the p53-dependent up-regulation of Notch1 in response to Nutlin-3 represents an antiapoptotic feedback mechanism able to restrain the potential therapeutic efficacy of Nutlin-3 in hematologic malignancies. "
01/01/2011 - "A series of recent studies have strengthened the concept that selective, non-genotoxic p53 activation by Nutlin-3 might represent an alternative to the current cytotoxic chemotherapy, in particular for pediatric tumors and for hematological malignancies, which retain a high percentage of p53(wild-type) status at diagnosis. "
01/01/2013 - "To overcome the poor bioavailability of Nutlin-3, we have assessed the potential efficacy of Nutlin-3 loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NP) against hematological malignancies. "
|5.||Melanoma (Melanoma, Malignant)
08/15/2013 - "Thirty-seven BRAF(V600E)-mutated melanoma lines were subjected to synergy studies in vitro using a combination of vemurafenib and nutlin-3 (Nt-3). "
02/01/2012 - "In this study, we showed that both p53 protein and activity levels in melanoma cells were strongly induced by nutlin-3, a canonical HDM2 antagonist. "
12/01/2010 - "However, we found in this study that blockade of the interaction of p53 and MDM2 by the MDM2 antagonist nutlin-3 in melanoma cells did not induce apoptosis, even though it upregulated p53 and its proapoptotic targets. "
12/01/2010 - "p53 activation in cultured primary melanocyte and melanoma cell lines using Nutlin-3, a specific Mdm2 antagonist, supported these findings. "
06/01/2010 - "In accord, in melanoma cell lines and mouse embryo fibroblasts, which easily undergo senescence in response to p53 activation, nutlin-3a failed to inhibit mTOR. "
|2.||Transferrin (beta 2 Transferrin)
|4.||2,2- bis(hydroxymethyl)- 1- azabicyclo(2,2,2,)octan- 3- one
|5.||Neurofibromin 2 (Merlin)
|8.||polylactic acid-polyglycolic acid copolymer (PLGA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Quantum Dots (Quantum Dot)